Dendritic Cell Trafficking in Tumor-bearing Mice

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2018 Jun 27

PMID 29943070

Citations 8

Authors

Sarah C Krzastek

Ekaterine Goliadze

Shaoqing Zhou

Albert Petrossian

Fatma Youniss

Gobalakrishnan Sundaresan

Li Wang

Jamal Zweit

Georgi Guruli

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is one of the leading causes of cancer deaths, with no curative treatments once it spreads. Alternative therapies, including immunotherapy, have shown limited efficacy. Dendritic cells (DC) have been widely used in the treatment of various malignancies. DC capture antigens and move to the lymphoid organs where they prime naive T cells. Interaction between DC and T cells are most active in lymph nodes and suppression of DC trafficking to lymph nodes impairs the immune response. In this work, we aimed to study trafficking of DC in vivo via various routes of delivery, to optimize the effectiveness of DC-based therapy. A DC labeling system was developed using 1,1'-dioctadecyltetramethyl indotricarbocyanine Iodine for in vivo fluorescent imaging. DC harvested from C57B/6 mice were matured, labeled, and injected intravenously, subcutaneously, or intratumorally, with or without antigen loading with whole tumor lysate, into C57B/6 mice inoculated with RM-1 murine prostate tumor cells. Signal intensity was measured in vivo and ex vivo. Signal intensity at the tumor site increased over time, suggesting trafficking of DC to the tumor with all modes of injection. Subcutaneous injection showed preferential trafficking to lymph nodes and tumor. Intravenous injection showed trafficking to lungs, intestines, and spleen. Subcutaneous injection of DC pulsed with whole tumor lysate resulted in the highest increase in signal intensity at the tumor site and lymph nodes, suggesting subcutaneous injection of primed DC leads to highest preferential trafficking of DC to the immunocompetent organs.

Citing Articles

Trial watch: anticancer vaccination with dendritic cells.

Borges F, Laureano R, Vanmeerbeek I, Sprooten J, Demeulenaere O, Govaerts J Oncoimmunology. 2024; 13(1):2412876.

PMID: 39398476 PMC: 11469433. DOI: 10.1080/2162402X.2024.2412876.

Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy.

Nguyen D, Song K, Jokonya S, Yazdani O, Sellers D, Wang Y ACS Cent Sci. 2024; 10(3):666-675.

PMID: 38559305 PMC: 10979423. DOI: 10.1021/acscentsci.3c01310.

The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model.

Geyer M, Gaul L, D Agosto S, Corbo V, Queiroz K Front Immunol. 2023; 14:1155085.

PMID: 37205118 PMC: 10185841. DOI: 10.3389/fimmu.2023.1155085.

A Microfluidic 3D Endothelium-on-a-Chip Model to Study Transendothelial Migration of T Cells in Health and Disease.

de Haan L, Suijker J, van Roey R, Berges N, Petrova E, Queiroz K Int J Mol Sci. 2021; 22(15).

PMID: 34361000 PMC: 8347346. DOI: 10.3390/ijms22158234.

AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma.

Fukuda K, Okamura K, Riding R, Fan X, Afshari K, Haddadi N J Exp Med. 2021; 218(9).

PMID: 34325468 PMC: 8329870. DOI: 10.1084/jem.20200962.

References

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

Jiang P, Zhang Y, J Archibald S, Wang H . Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol. 2015; 28(1):208-14. DOI: 10.1016/j.intimp.2015.05.042. View

Vicari A, Treilleux I, Lebecque S . Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol. 2004; 14(3):161-9. DOI: 10.1016/j.semcancer.2003.10.002. View

Bregy A, Wong T, Shah A, Goldberg J, Komotar R . Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev. 2013; 39(8):891-907. DOI: 10.1016/j.ctrv.2013.05.007. View

Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A . Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One. 2011; 6(4):e18801. PMC: 3080391. DOI: 10.1371/journal.pone.0018801. View

Sozzani S, Luini W, Borsatti A, Polentarutti N, Zhou D, Piemonti L . Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol. 1997; 159(4):1993-2000. View

Randolph G, Angeli V, Swartz M . Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005; 5(8):617-28. DOI: 10.1038/nri1670. View

Smithson G, Rogers C, Smith P, Scheidegger E, Petryniak B, Myers J . Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes. J Exp Med. 2001; 194(5):601-14. PMC: 2195944. DOI: 10.1084/jem.194.5.601. View

Segura E, Albiston A, Wicks I, Chai S, Villadangos J . Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci U S A. 2009; 106(48):20377-81. PMC: 2787113. DOI: 10.1073/pnas.0910295106. View

10.

Caux C, Chemin K, de Bouteiller O, Dieu-Nosjean M, Homey B, Massacrier C . Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol. 2001; 22(4):345-69. DOI: 10.1007/s002810000053. View

11.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

12.

Di Lorenzo G, Buonerba C, Kantoff P . Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol. 2011; 8(9):551-61. DOI: 10.1038/nrclinonc.2011.72. View

13.

Yang J, Rosenberg S . Adoptive T-Cell Therapy for Cancer. Adv Immunol. 2016; 130:279-94. PMC: 6293459. DOI: 10.1016/bs.ai.2015.12.006. View

14.

Tacken P, de Vries I, Torensma R, Figdor C . Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007; 7(10):790-802. DOI: 10.1038/nri2173. View

15.

Del Prete A, Shao W, Mitola S, Santoro G, Sozzani S, Haribabu B . Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood. 2006; 109(2):626-31. PMC: 1785104. DOI: 10.1182/blood-2006-02-003665. View

16.

Galustian C, Vyakarnam A, Elhage O, Hickman O, Dasgupta P, Smith R . Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins. Biochem Soc Trans. 2011; 39(5):1433-6. DOI: 10.1042/BST0391433. View

17.

Datta J, Terhune J, Lowenfeld L, Cintolo J, Xu S, Roses R . Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med. 2014; 87(4):491-518. PMC: 4257036. View

18.

Zhang L, Zhu W, Li J, Yang X, Ren Y, Niu J . Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. Mol Clin Oncol. 2016; 4(1):129-133. PMC: 4727101. DOI: 10.3892/mco.2015.660. View

19.

Silvestri I, Cattarino S, Agliano A, Collalti G, Sciarra A . Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. Biomed Res Int. 2015; 2015:794968. PMC: 4486485. DOI: 10.1155/2015/794968. View

20.

Anguille S, Smits E, Lion E, Van Tendeloo V, Berneman Z . Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15(7):e257-67. DOI: 10.1016/S1470-2045(13)70585-0. View